0H79 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Very Low LeverageDebt of only ~$2.5M against ~$1.11B of equity gives Oruka substantial balance-sheet flexibility for clinical development and investment. The sharply higher ~$1.14B asset base also indicates a materially strengthened capital position, although returns remain negative.
Commercial Leadership InvestmentAdding a veteran commercial executive with dermatology and immunology biologics experience is a concrete investment in future launch readiness. This leadership capability can strengthen commercialization planning as candidates advance, while multi-year equity awards align incentives with execution.
Clear Cash-burn ProfileFree cash flow tracking net loss at roughly 1.0x suggests reported losses broadly reflect cash investment rather than large non-cash charges. That makes funding needs easier to assess and provides a clearer baseline for judging whether clinical progress improves cash economics.
Bears Say
Pre-revenue Business ModelWith $0 revenue in annual periods and TTM, Oruka has no product-sales base to fund operations. Its financial model therefore depends on clinical progress leading to future revenue, partnerships, or financing, leaving near-term earnings and self-funded growth unavailable.
Widening LossesNet loss widened from ~$83.7M in 2024 to ~$105.4M in 2025 and ~$132.9M TTM, while operating losses also expanded. This trajectory shows rising investment before commercialization and keeps profitability dependent on successful development and eventual revenue generation.
Accelerating Cash BurnFree cash flow deteriorated from about -$58.0M in 2024 to -$88.4M in 2025 and -$101.2M TTM. Continuing acceleration increases reliance on the strong capital base, future financing, or partnering inflows to sustain clinical programs over the next several quarters.
Oruka Therapeutics News
0H79 FAQ
What was Oruka Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Oruka Therapeutics’s market cap?
Oruka Therapeutics’s market cap is $5.66B.
When is Oruka Therapeutics’s upcoming earnings report date?
Oruka Therapeutics’s upcoming earnings report date is Nov 18, 2026 which is in 53 days.
How were Oruka Therapeutics’s earnings last quarter?
Oruka Therapeutics released its earnings results on Aug 10, 2026. The company reported -$0.55 earnings per share for the quarter, missing the consensus estimate of -$0.512 by -$0.038.
Is Oruka Therapeutics overvalued?
According to Wall Street analysts Oruka Therapeutics’s price is currently Undervalued.
Does Oruka Therapeutics pay dividends?
Oruka Therapeutics does not currently pay dividends.
What is Oruka Therapeutics’s EPS estimate?
Oruka Therapeutics’s EPS estimate is -0.6.
How many shares outstanding does Oruka Therapeutics have?
Oruka Therapeutics has 66,209,700 shares outstanding.
What happened to Oruka Therapeutics’s price movement after its last earnings report?
Oruka Therapeutics reported an EPS of -$0.55 in its last earnings report, missing expectations of -$0.512. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Oruka Therapeutics?
Currently, no hedge funds are holding shares in GB:0H79
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Oruka Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$154.09 (― Upside)
$154.09 (― Upside)
Blogger Sentiment
Bullish
GB:0H79 Sentiment 67%
Sector Average 63%
Sector Average 63%
Insider Transactions
Sold Shares
Worth $300.4M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 83%
Bearish news 17%
Bearish news 17%
Technicals
SMA
Positive
20 days / 200 days
Momentum
461.19%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
218.78%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Oruka Therapeutics
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
0H79 Stock 12 Month Forecast
Average Price Target
―Verastem
―
AnaptysBio
―
Compass Therapeutics
―
Olema Pharmaceuticals
―
Bicara Therapeutics Inc.
―